Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease



Rating:

Share or cite this content

Citations should be made in the following way:
A. Pakhlavonova (Moscow, Russian Federation), V. Aksenova (Moscow, Russian Federation), N. Klevno (Moscow, Russian Federation), A. Kazakov (Moscow, Russian Federation), S. Popov (Moscow, Russian Federation), V. Hotchenkov (Moscow, Russian Federation), A. Ruzhitsky (Moscow, Russian Federation). Comparison of the Pharmacokinetics of a child-friendly Fixed-Dose Combination of rifampin and isoniazid and separate tablets in children with pulmonary tuberculosis.. 1604

Member's Comments

No comment yet.

Related content which might interest you: High-dose rifampicin and rifapentine in tuberculosis treatment Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015 Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012 Efficacy of intravenous isoniazid, rifampin and ethambutol administration in patients with failed treatment of tuberculosis and malabsorption syndrome Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016 Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules Source: Eur Respir J, 54 (6) 1900580; 10.1183/13993003.00580-2019 Year: 2019 Efficacy and safety of isoniazid in syrup form for IPT in children Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017 Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine Source: Eur Respir J 2016; 48: 1527-1529 Year: 2016 Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine Source: Eur Respir J 2016; 48: 1526-1527 Year: 2016 Tolerance of cycloserine in combined therapy of tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001 Efficacy of moxifloxacin in TB resistant to isoniazid Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience Source: Eur Respir J 2011; 38: 888-894 Year: 2011 Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006 Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016 Year: 2017 Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016 Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Susceptibility of mycobacterium avium complex and mycobacterium xenopi to rifampin, rifapentine, clarithromycin and moxifloxacin, alone or in combination with ethambutol Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002 Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601612; DOI: 10.1183/13993003.01612-2016 Year: 2017